The safety of bevazicumab for the treatment of ovarian cancer

Carolina Bottoni, Giovanni Scambia, Anna Fagotti, Marco Petrillo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: The safety profile of bevacizumab (BV) remains a challenging issue, in particular its role in fragile OC patients. Areas covered: In this literature review, we have analyzed safety data from Phase III trials evaluating the combination of BV plus standard chemotherapy in advanced or recurrent OC patients. In particular, our review aimed at clarifying the impact of the drug on fragile patients, and the correlation between BV and postoperative complications after cytoreductive surgery. Expert opinion: The addition of BV to standard chemotherapy regimens may cause unexpected side effects such as hypertension or proteinuria in up to 10% of women receiving the drug. BV administration is not associated with increase postoperative complications after cytoreductive surgery. Artero-venous thromboembolism and gastrointestinal perforation/fistula occurring in around 3% of OC patients treated with BV represent life-threatening events always requiring drug suspension. A closer monitoring is required in selected groups of women including: women with inflammatory bowel disease, or uncontrolled hypertension. Age itself is not a major contraindication, but older women should be carefully evaluated prior to start the drug. Finally, BV maintenance therapy should not be prematurely stopped due to minor events, since drug suspension may reduce survival.

Original languageEnglish
Pages (from-to)1107-1113
Number of pages7
JournalExpert Opinion on Drug Safety
Volume17
Issue number11
DOIs
Publication statusPublished - Nov 2 2018

Fingerprint

Ovarian Neoplasms
Safety
Pharmaceutical Preparations
Therapeutics
Suspensions
Hypertension
Drug Therapy
Venous Thromboembolism
Expert Testimony
Bevacizumab
Inflammatory Bowel Diseases
Proteinuria
Fistula
Survival

Keywords

  • Bevacizumab
  • complications
  • cytoreductive surgery
  • elderly patients
  • fragility
  • gastrointestinal disease
  • gynecological cancer
  • ovarian cancer
  • recurrent disease

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The safety of bevazicumab for the treatment of ovarian cancer. / Bottoni, Carolina; Scambia, Giovanni; Fagotti, Anna; Petrillo, Marco.

In: Expert Opinion on Drug Safety, Vol. 17, No. 11, 02.11.2018, p. 1107-1113.

Research output: Contribution to journalArticle

Bottoni, Carolina ; Scambia, Giovanni ; Fagotti, Anna ; Petrillo, Marco. / The safety of bevazicumab for the treatment of ovarian cancer. In: Expert Opinion on Drug Safety. 2018 ; Vol. 17, No. 11. pp. 1107-1113.
@article{f0ced87138ff411082cb09948a5fb0a5,
title = "The safety of bevazicumab for the treatment of ovarian cancer",
abstract = "Introduction: The safety profile of bevacizumab (BV) remains a challenging issue, in particular its role in fragile OC patients. Areas covered: In this literature review, we have analyzed safety data from Phase III trials evaluating the combination of BV plus standard chemotherapy in advanced or recurrent OC patients. In particular, our review aimed at clarifying the impact of the drug on fragile patients, and the correlation between BV and postoperative complications after cytoreductive surgery. Expert opinion: The addition of BV to standard chemotherapy regimens may cause unexpected side effects such as hypertension or proteinuria in up to 10{\%} of women receiving the drug. BV administration is not associated with increase postoperative complications after cytoreductive surgery. Artero-venous thromboembolism and gastrointestinal perforation/fistula occurring in around 3{\%} of OC patients treated with BV represent life-threatening events always requiring drug suspension. A closer monitoring is required in selected groups of women including: women with inflammatory bowel disease, or uncontrolled hypertension. Age itself is not a major contraindication, but older women should be carefully evaluated prior to start the drug. Finally, BV maintenance therapy should not be prematurely stopped due to minor events, since drug suspension may reduce survival.",
keywords = "Bevacizumab, complications, cytoreductive surgery, elderly patients, fragility, gastrointestinal disease, gynecological cancer, ovarian cancer, recurrent disease",
author = "Carolina Bottoni and Giovanni Scambia and Anna Fagotti and Marco Petrillo",
year = "2018",
month = "11",
day = "2",
doi = "10.1080/14740338.2018.1532500",
language = "English",
volume = "17",
pages = "1107--1113",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - The safety of bevazicumab for the treatment of ovarian cancer

AU - Bottoni, Carolina

AU - Scambia, Giovanni

AU - Fagotti, Anna

AU - Petrillo, Marco

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Introduction: The safety profile of bevacizumab (BV) remains a challenging issue, in particular its role in fragile OC patients. Areas covered: In this literature review, we have analyzed safety data from Phase III trials evaluating the combination of BV plus standard chemotherapy in advanced or recurrent OC patients. In particular, our review aimed at clarifying the impact of the drug on fragile patients, and the correlation between BV and postoperative complications after cytoreductive surgery. Expert opinion: The addition of BV to standard chemotherapy regimens may cause unexpected side effects such as hypertension or proteinuria in up to 10% of women receiving the drug. BV administration is not associated with increase postoperative complications after cytoreductive surgery. Artero-venous thromboembolism and gastrointestinal perforation/fistula occurring in around 3% of OC patients treated with BV represent life-threatening events always requiring drug suspension. A closer monitoring is required in selected groups of women including: women with inflammatory bowel disease, or uncontrolled hypertension. Age itself is not a major contraindication, but older women should be carefully evaluated prior to start the drug. Finally, BV maintenance therapy should not be prematurely stopped due to minor events, since drug suspension may reduce survival.

AB - Introduction: The safety profile of bevacizumab (BV) remains a challenging issue, in particular its role in fragile OC patients. Areas covered: In this literature review, we have analyzed safety data from Phase III trials evaluating the combination of BV plus standard chemotherapy in advanced or recurrent OC patients. In particular, our review aimed at clarifying the impact of the drug on fragile patients, and the correlation between BV and postoperative complications after cytoreductive surgery. Expert opinion: The addition of BV to standard chemotherapy regimens may cause unexpected side effects such as hypertension or proteinuria in up to 10% of women receiving the drug. BV administration is not associated with increase postoperative complications after cytoreductive surgery. Artero-venous thromboembolism and gastrointestinal perforation/fistula occurring in around 3% of OC patients treated with BV represent life-threatening events always requiring drug suspension. A closer monitoring is required in selected groups of women including: women with inflammatory bowel disease, or uncontrolled hypertension. Age itself is not a major contraindication, but older women should be carefully evaluated prior to start the drug. Finally, BV maintenance therapy should not be prematurely stopped due to minor events, since drug suspension may reduce survival.

KW - Bevacizumab

KW - complications

KW - cytoreductive surgery

KW - elderly patients

KW - fragility

KW - gastrointestinal disease

KW - gynecological cancer

KW - ovarian cancer

KW - recurrent disease

UR - http://www.scopus.com/inward/record.url?scp=85054724535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054724535&partnerID=8YFLogxK

U2 - 10.1080/14740338.2018.1532500

DO - 10.1080/14740338.2018.1532500

M3 - Article

C2 - 30286624

AN - SCOPUS:85054724535

VL - 17

SP - 1107

EP - 1113

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 11

ER -